Formosa Pharmaceuticals Investors
Consolidated Financial Statements
Parent Company Only Financial Statements
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery.
TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the second of the two pivotal Phase 3 clinical studies of